Photo from Angelo Pirozzi/X
Jun 9, 2024, 09:31
Angelo Pirozzi: Update on FIGHT-202
Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X:
“Update on FIGHT-202
145 patients with pretreated advanced CCA and FGFR2 alterations received pemigatinib
Median follow-up 45 mos For FGFR2 fusions:
- ORR 37%
- mDOR 9.1 mos
- mPFS 7.0 mos
- mOS 17.5 mos
- 10.2% TEAEs led to discontinuation.“
Read further.
Source: Angelo Pirozzi/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14